Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP4 | P49662 | 1/20 | 0.43 |
| ▸ | CASP5 | P51878 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5797268 | 0.82 | ADRB1 (0.59) | ADRB1KDM4EALDH1A1ACHEHRH3 | |
| SCHEMBL31518606 | 0.82 | ADRB1 (0.59) | ADRB1KDM4EALDH1A1ACHEHRH3 | |
| Hydrochloric Acid SCHEMBL5375047 | 0.81 | KDM4E (0.59) | ADRB1KDM4EALDH1A1ACHEHRH3 | |
| Hydrochloric Acid SCHEMBL7868157 | 0.81 | KDM4E (0.59) | ADRB1KDM4EALDH1A1ACHEHRH3 | |
| SCHEMBL11113633 | 0.80 | ADRB1 (0.61) | ADRB1KDM4EALDH1A1ACHEHRH3 | |
| SCHEMBL573580 | 0.79 | ADRB1 (0.59) | ADRB1KDM4EALDH1A1ACHEHRH3 | |
| SCHEMBL5758330 | 0.79 | ADRB1 (0.59) | ADRB1KDM4EALDH1A1ACHEHRH3 | |
| SCHEMBL4501470 | 0.79 | ADRB1 (0.59) | ADRB1KDM4EALDH1A1ACHEHRH3 | |
| SCHEMBL13361845 | 0.78 | ADRB1 (0.59) | ADRB1KDM4EALDH1A1ACHEHRH3 | |
| SCHEMBL230177 | 0.78 | ADRB1 (1.00) | ADRB1KDM4EALDH1A1ACHEHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238643-B2 | Amide compounds | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2016-01-19 | — | — | US | disclosed |
| US-20130245033-A1 | AMIDE COMPOUNDS | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2013-09-19 | — | — | US | disclosed |
| US-6372762-B1 | HETEROCYCLIC COMPOUNDS FOR NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-04-16 | — | — | US | disclosed |
| US-20020019401-A1 | Substituted bicyclic derivatives for treating central nervous system disorders | FLIRI ANTON FRANZ JOSEPH (US) | 2002-02-14 | — | — | US | disclosed |
| EP-0953567-A2 | Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity | Pfizer Products Inc. (US) | 1999-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245033-A1 | AMIDE COMPOUNDS | AR, AVPR2, H1-0 | ADRB1 32/4885KDM4E 2212/4885ALDH1A1 654/4885 |
| US-20020019401-A1 | Substituted bicyclic derivatives for treating central nervous system disorders | OPRK1, OPRD1, MC2R | ADRB1 94/4885KDM4E 1783/4885ALDH1A1 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.